Adverum Biotechnologies, Inc. (ADVM) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ADVM Revenue Growth
Revenue Breakdown (FY 2024)
ADVM's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
ADVM Revenue Analysis (2013–2024)
As of May 8, 2026, Adverum Biotechnologies, Inc. (ADVM) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, ADVM's 5-year compound annual growth rate (CAGR) stands at +32.0%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $7.5 million in 2021.
Revenue diversification analysis shows ADVM's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including OCGN (+8.8% YoY), KRYS (+25.1% YoY), and RARE (+13.3% YoY), ADVM has underperformed the peer group in terms of revenue growth. Compare ADVM vs OCGN →
ADVM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ADVMCurrent | $0 | -100.0% | +32.0% | -13915.9% | |
 OCGN | $4M | +8.8% | +152.5% | -1425.7% | |
 KRYS | $389M | +25.1% | - | 41.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% |
ADVM Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.0M | -72.2% | $1.0M | 100.0% | $-139,159,000 | -13915.9% |
| 2023 | $3.6M | - | $3.6M | 100.0% | $-128,942,000 | -3581.7% |
| 2022 | $0 | -100.0% | $0 | - | $-157,135,000 | - |
| 2021 | $7.5M | - | $7.5M | 100.0% | $-146,122,000 | -1948.3% |
| 2020 | $0 | -100.0% | $-4,158,000 | - | $-117,950,000 | - |
| 2019 | $250K | -84.5% | $0 | - | $-68,545,000 | -27418.0% |
| 2018 | $1.6M | -12.8% | $0 | - | $-78,081,000 | -4843.7% |
| 2017 | $1.8M | +27.1% | $0 | - | $-58,847,000 | -3182.6% |
| 2016 | $1.5M | -37.3% | $0 | - | $-115,284,000 | -7923.3% |
| 2015 | $2.3M | +305.4% | $2.3M | 100.0% | $-47,823,000 | -2062.2% |
See ADVM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADVM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ADVM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonADVM — Frequently Asked Questions
Quick answers to the most common questions about buying ADVM stock.
Is ADVM's revenue growth accelerating or slowing?
ADVM revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +32.0%. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is ADVM's long-term revenue growth rate?
Adverum Biotechnologies, Inc.'s 5-year revenue CAGR of +32.0% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is ADVM's revenue distributed by segment?
ADVM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.